Stock Analysts

Haemonetics’ (HAE) Q3 Earnings Top Estimates, EPS View Up

Haemonetics Corporation HAE reported adjusted earnings per share (EPS) of 62 cents in the third quarter of fiscal 2018, a 44% surge year over year. The bottom line also beat the Zacks Consensus Estimate of 41 cents. The metric was favourably attributed by 10 cents of lower tax rate and 4 cents of currency translation, partly offset by a couple of cents’ dilution on increased share count […]

Stock Analysts

Add These 7 GARP Stocks to Your Portfolio for Better Returns

Growth at a reasonable price or GARP is an excellent way for investors to make some quick gains. This strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount. The GARP approach leads to the identification of stocks that are priced below the market or any reasonable target determined by fundamental analysis. […]

Stock Analysts

Snap (SNAP) Q4 Earnings and Revenues Surpass Estimates

Snap Inc. SNAP reported loss per share of 13 cents, which was narrower than the Zacks Consensus Estimate of a loss of 15 cents and the year-ago quarter’s loss of 19 cents. The company reported revenues of $285.7 million, which came ahead of the consensus mark of $251.7 million and grew 72.4% year over year […]

Stock Analysts

REGN vs. ALXN: Which Stock is Poised for Better Q4 Earnings?

The fourth-quarter earnings season has crossed the halfway mark. So far, the results reflect a favorable trend, with an above average proportion of companies beating both top- and bottom-line expectations. Per the latest Earnings Preview , total earnings for the 251 S&P members that have released results, are up 16% from the year-ago quarter on a 10.5% rise in revenues. […]

Stock Analysts

Liberty (LPT) Q4 FFO & Revenues Beat Estimates, Stock Up

Liberty Property Trust LPT reported fourth-quarter 2017 funds from operations (FFO) per share of 68 cents, which surpassed the Zacks Consensus Estimate of 65 cents. Total operating revenues of around $192.8 million for the quarter also outpaced the Zacks Consensus Estimate of $173.0 million. On a year-over-year basis, the company’s FFO per share climbed from 41 cents per share recorded in the year-earlier quarter, while total operating revenues increased 13.6% year over year […]

Stock Analysts

CAH vs. HOLX: Which Will Fare Better This Earnings Season?

We are in the thick of the fourth-quarter earnings season, with 251 S&P 500 members having reported their numbers. The current earnings season has seen an above-average proportion of positive surprises, a favorable revision trend for the present and upcoming quarter along with a strong revenue momentum. Per the latest Earnings Preview , total earnings for the companies that have reported so far are up 16% year over year on 10.5% higher revenues. […]

Stock Analysts

Array’s Melanoma Combo Shows Positive Overall Survival Data

Array BioPharma Inc. 's ARRY shares increased more than 15% on Feb 6 after it announced encouraging overall survival (OS) data from a pivotal phase III study evaluating COMBO450, a combination medicine of binimetinib and encorafenib. Array along with partner Pierre Fabre have developed the combo therapy for treating patients with BRAF-mutant advanced, unresectable or metastatic melanoma. […]